{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:37:56Z","timestamp":1790206676427,"version":"4.1.0"},"reference-count":206,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,5,19]],"date-time":"2010-05-19T00:00:00Z","timestamp":1274227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,5,19]],"date-time":"2010-05-19T00:00:00Z","timestamp":1274227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s12072-010-9183-5","type":"journal-article","created":{"date-parts":[[2010,5,18]],"date-time":"2010-05-18T13:07:31Z","timestamp":1274188051000},"page":"475-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management"],"prefix":"10.1007","volume":"4","author":[{"given":"Ye H.","family":"Oo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan G.","family":"Hubscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,5,19]]},"reference":[{"issue":"3","key":"9183_CR1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.21074","volume":"43","author":"AJ Czaja","year":"2006","unstructured":"Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006;43(3):532\u2013538","journal-title":"Hepatology"},{"issue":"3","key":"9183_CR2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2036.2006.03013.x","volume":"24","author":"Y Miyake","year":"2006","unstructured":"Miyake Y, Iwasaki Y, Sakaguchi K, Shiratori Y. Clinical features of Japanese male patients with type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006;24(3):519\u2013523","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"9183_CR3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jhep.2006.04.007","volume":"45","author":"T Al Chalabi","year":"2006","unstructured":"Al Chalabi T, Boccato S, Portmann BC, Mcfarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006;45(4):575\u2013583","journal-title":"J Hepatol"},{"issue":"9","key":"9183_CR4","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/j.1365-2036.2006.02894.x","volume":"23","author":"Y Miyake","year":"2006","unstructured":"Miyake Y, Iwasaki Y, Terada R, Onishi T, Okamoto R, Sakai N, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther 2006;23(9):1347\u20131353","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"9183_CR5","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0168-8278(94)80251-3","volume":"21","author":"GA Nikias","year":"1994","unstructured":"Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21(5):866\u2013871","journal-title":"J Hepatol"},{"issue":"6","key":"9183_CR6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00000478-199506000-00010","volume":"19","author":"LJ Burgart","year":"1995","unstructured":"Burgart LJ, Batts KP, Ludwig J, Nikias GA, Czaja AJ. Recent onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol 1995;19(6):699\u2013708","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"9183_CR7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/MCG.0b013e318176b8c5","volume":"43","author":"DR Terrabuio","year":"2009","unstructured":"Terrabuio DR, Abrantes-Lemos CP, Carrilho FJ, Cancado EL. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol 2009;43(4):350\u2013356","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"9183_CR8","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/00365520601155266","volume":"42","author":"M Werner","year":"2007","unstructured":"Werner M, Bjornsson E, Prytz H, Lindgren S, Almer S, Broome U, et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol 2007;42(8):986\u2013991","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"9183_CR9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1572-0241.2006.00479.x","volume":"101","author":"C Schramm","year":"2006","unstructured":"Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse AW. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006;101(3):556\u2013560","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"9183_CR10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/gut.48.1.97","volume":"48","author":"MA Heneghan","year":"2001","unstructured":"Heneghan MA, Norris SM, O\u2019Grady JG, Harrison PM, Mcfarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001;48(1):97\u2013102","journal-title":"Gut"},{"issue":"3","key":"9183_CR11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/ni1037","volume":"5","author":"VR Aluvihare","year":"2004","unstructured":"Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004;5(3):266\u2013271","journal-title":"Nat Immunol"},{"issue":"10","key":"9183_CR12","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1365-2036.2005.02686.x","volume":"22","author":"M Fusconi","year":"2005","unstructured":"Fusconi M, Vannini A, Dall\u2019Aglio AC, Pappas G, Cassani F, Ballardini G, et al. Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2005;22(10):951\u2013955","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"9183_CR13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/08916930600783348","volume":"39","author":"A Montano-Loza","year":"2006","unstructured":"Montano-Loza A, Czaja AJ, Carpenter HA, Piette A, Murphy D, Shums Z, et al. Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis. Autoimmunity 2006;39(4):341\u2013348","journal-title":"Autoimmunity"},{"issue":"3","key":"9183_CR14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1572-0241.2000.01863.x","volume":"95","author":"Z Ben-Ari","year":"2000","unstructured":"Ben-Ari Z, Broida E, Monselise Y, Kazatsker A, Baruch J, Pappo O, et al. Syncytial giant-cell hepatitis due to autoimmune hepatitis type II (LKM1+) presenting as subfulminant hepatitis. Am J Gastroenterol 2000;95(3):799\u2013801","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"9183_CR15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/hep.1840160208","volume":"16","author":"K Devaney","year":"1992","unstructured":"Devaney K, Goodman ZD, Ishak KG. Postinfantile giant-cell transformation in hepatitis. Hepatology 1992;16(2):327\u2013333","journal-title":"Hepatology"},{"issue":"3","key":"9183_CR16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1089-3261(02)00022-3","volume":"6","author":"HA Carpenter","year":"2002","unstructured":"Carpenter HA, Czaja AJ. The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants. Clin Liver Dis 2002;6(3):685\u2013705","journal-title":"Clin Liver Dis"},{"key":"9183_CR17","unstructured":"Burt AD, Portmann BC, Ferrell LD, MacSween R. Autoimmune hepatitis. In Pathology of the Liver. Edinburgh: Churchill Livingstone; 2007. 493\u2013517"},{"issue":"1","key":"9183_CR18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/hep.20732","volume":"42","author":"JJ Feld","year":"2005","unstructured":"Feld JJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42(1):53\u201362","journal-title":"Hepatology"},{"issue":"5","key":"9183_CR19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00004836-200105000-00014","volume":"32","author":"SJ Cotler","year":"2001","unstructured":"Cotler SJ, Jakate S, Jensen DM. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001;32(5):428\u2013430","journal-title":"J Clin Gastroenterol"},{"issue":"4","key":"9183_CR20","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2004.01.009","volume":"40","author":"AJ Czaja","year":"2004","unstructured":"Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40(4):646\u2013652","journal-title":"J Hepatol"},{"issue":"6","key":"9183_CR21","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.20235","volume":"39","author":"AJ Czaja","year":"2004","unstructured":"Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004;39(6):1631\u20131638","journal-title":"Hepatology"},{"issue":"4","key":"9183_CR22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.1840180435","volume":"18","author":"PJ Johnson","year":"1993","unstructured":"Johnson PJ, Mcfarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18(4):998\u20131005","journal-title":"Hepatology"},{"issue":"5","key":"9183_CR23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5):929\u2013938","journal-title":"J Hepatol"},{"issue":"1","key":"9183_CR24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48(1):169\u2013176","journal-title":"Hepatology"},{"issue":"5","key":"9183_CR25","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/hep.22513","volume":"48","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Performance parameters of the diagnostic scoring systems for autoimmune hepatitis. Hepatology 2008;48(5):1540\u20131548","journal-title":"Hepatology"},{"issue":"2","key":"9183_CR26","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/hep.23042","volume":"50","author":"AD Yeoman","year":"2009","unstructured":"Yeoman AD, Westbrook RH, Al-Chalabi T, Carey I, Heaton ND, Portmann BC, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009;50(2):538\u2013545","journal-title":"Hepatology"},{"issue":"3","key":"9183_CR27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0029-1233532","volume":"29","author":"C Wiegard","year":"2009","unstructured":"Wiegard C, Schramm C, Lohse AW. Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future. Semin Liver Dis 2009;29(3):254\u2013261","journal-title":"Semin Liver Dis"},{"issue":"5","key":"9183_CR28","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0168-8278(00)80241-X","volume":"32","author":"C Roozendaal","year":"2000","unstructured":"Roozendaal C, de Jong MA, van den Berg AP, van Wijk RT, Limburg PC, Kallenberg CG. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 2000;32(5):734\u2013741","journal-title":"J Hepatol"},{"issue":"30","key":"9183_CR29","first-page":"3034","volume":"46","author":"C Roozendaal","year":"1999","unstructured":"Roozendaal C, Kallenberg CG. Anti-neutrophil cytoplasm autoantibodies (ANCA) in autoimmune liver diseases. Hepatogastroenterology 1999;46(30):3034\u20133040","journal-title":"Hepatogastroenterology"},{"issue":"11","key":"9183_CR30","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1111\/j.1572-0241.2000.03207.x","volume":"95","author":"A Duchini","year":"2000","unstructured":"Duchini A, McHutchison JG, Pockros PJ. LKM-positive autoimmune hepatitis in the western United States: a case series. Am J Gastroenterol 2000;95(11):3238\u20133241","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"9183_CR31","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1542-3565(04)00354-4","volume":"2","author":"L Bridoux-Henno","year":"2004","unstructured":"Bridoux-Henno L, Maggiore G, Johanet C, Fabre M, Vajro P, Dommergues JP, et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004;2(9):825\u2013830","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9214","key":"9183_CR32","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/S0140-6736(00)02166-8","volume":"355","author":"I Wies","year":"2000","unstructured":"Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Buschenfelde KH, et al. Identification of target antigen for SLA\/LP autoantibodies in autoimmune hepatitis. Lancet 2000;355(9214):1510\u20131515","journal-title":"Lancet"},{"issue":"4","key":"9183_CR33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0168-8278(99)80342-0","volume":"31","author":"S Kanzler","year":"1999","unstructured":"Kanzler S, Weidemann C, Gerken G, Lohr HF, Galle PR, Meyer zum Buschenfelde KH, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999;31(4):635\u2013640","journal-title":"J Hepatol"},{"issue":"1","key":"9183_CR34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.21.1.78","volume":"21","author":"AP Kirk","year":"1980","unstructured":"Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980;21(1):78\u201383","journal-title":"Gut"},{"issue":"7806","key":"9183_CR35","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","volume":"1","author":"IM Murray-Lyon","year":"1973","unstructured":"Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1(7806):735\u2013737","journal-title":"Lancet"},{"issue":"1","key":"9183_CR36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004836-200207000-00016","volume":"35","author":"J Kogan","year":"2002","unstructured":"Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J Clin Gastroenterol 2002;35(1):75\u201381","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"9183_CR37","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/j.1572-0241.2004.30457.x","volume":"99","author":"S Verma","year":"2004","unstructured":"Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004;99(8):1510\u20131516","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"9183_CR38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/hep.22432","volume":"48","author":"AD Yeoman","year":"2008","unstructured":"Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening. Hepatology 2008;48(3):863\u2013870","journal-title":"Hepatology"},{"issue":"4","key":"9183_CR39","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.510290409","volume":"29","author":"AW Lohse","year":"1999","unstructured":"Lohse AW, zum Buschenfelde KH, Franz B, Kanzler S, Gerken G, Dienes HP. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology 1999;29(4):1078\u20131084","journal-title":"Hepatology"},{"issue":"4","key":"9183_CR40","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0168-8278(00)80004-5","volume":"33","author":"M Kaya","year":"2000","unstructured":"Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000;33(4):537\u2013542","journal-title":"J Hepatol"},{"issue":"5","key":"9183_CR41","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1572-0241.2002.05703.x","volume":"97","author":"JA Talwalkar","year":"2002","unstructured":"Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002;97(5):1191\u20131197","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"9183_CR42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-2005-916322","volume":"25","author":"U Beuers","year":"2005","unstructured":"Beuers U, Rust C. Overlap syndromes. Semin Liver Dis 2005;25(3):311\u2013320","journal-title":"Semin Liver Dis"},{"issue":"6","key":"9183_CR43","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.1840360615","volume":"36","author":"AA Abdo","year":"2002","unstructured":"Abdo AA, Bain VG, Kichian K, Lee SS. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002;36(6):1393\u20131399","journal-title":"Hepatology"},{"issue":"3","key":"9183_CR44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nri1784","volume":"6","author":"DH Adams","year":"2006","unstructured":"Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006;6(3):244\u2013251","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"9183_CR45","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1053\/jhep.2000.8376","volume":"31","author":"P Bertolino","year":"2000","unstructured":"Bertolino P, Klimpel G, Lemon SM. Hepatic inflammation and immunity: a summary of a conference on the function of the immune system within the liver. Hepatology 2000;31(6):1374\u20131378","journal-title":"Hepatology"},{"issue":"2","key":"9183_CR46","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","volume":"44","author":"O Chazouilleres","year":"2006","unstructured":"Chazouilleres O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2006;44(2):400\u2013406","journal-title":"J Hepatol"},{"issue":"1","key":"9183_CR47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.21229","volume":"44","author":"R Poupon","year":"2006","unstructured":"Poupon R, Chazouilleres O, Corpechot C, Chretien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006;44(1):85\u201390","journal-title":"Hepatology"},{"issue":"3","key":"9183_CR48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3748\/wjg.14.331","volume":"14","author":"R Saich","year":"2008","unstructured":"Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol 2008;14(3):331\u2013337","journal-title":"World J Gastroenterol"},{"issue":"2\u20133","key":"9183_CR49","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0168-8278(92)90178-R","volume":"14","author":"R Perdigoto","year":"1992","unstructured":"Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992;14(2\u20133):325\u2013331","journal-title":"J Hepatol"},{"issue":"5","key":"9183_CR50","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1572-0241.1998.224_a.x","volume":"93","author":"AN McNair","year":"1998","unstructured":"McNair AN, Moloney M, Portmann BC, Williams R, Mcfarlane IG. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998;93(5):777\u2013784","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"9183_CR51","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1034\/j.1600-0641.2000.033004543.x","volume":"33","author":"HR van Buuren","year":"2000","unstructured":"van Buuren HR, van Hoogstraten HJE, Terkivatan T, Schalm SW, Vleggaar FP. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000;33(4):543\u2013548","journal-title":"J Hepatol"},{"issue":"9301","key":"9183_CR52","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0140-6736(02)07374-9","volume":"359","author":"AJ Grant","year":"2002","unstructured":"Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002;359(9301):150\u2013157","journal-title":"Lancet"},{"issue":"11","key":"9183_CR53","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.it.2008.08.003","volume":"29","author":"WW Agace","year":"2008","unstructured":"Agace WW. T-cell recruitment to the intestinal mucosa. Trends Immunol 2008;29(11):514\u2013522","journal-title":"Trends Immunol"},{"issue":"11","key":"9183_CR54","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1084\/jem.20041035","volume":"200","author":"B Eksteen","year":"2004","unstructured":"Eksteen B, Grant AJ, Miles A, Curbishley SM, Lalor PF, Hubscher SG, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 2004;200(11):1511\u20131517","journal-title":"J Exp Med"},{"issue":"3","key":"9183_CR55","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1053\/jhep.2001.22131","volume":"33","author":"GV Gregorio","year":"2001","unstructured":"Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis\/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33(3):544\u2013553","journal-title":"Hepatology"},{"issue":"4 Pt 1","key":"9183_CR56","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1053\/jhep.2001.27562","volume":"34","author":"AJ Czaja","year":"2001","unstructured":"Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001;34(4 Pt 1):659\u2013865","journal-title":"Hepatology"},{"issue":"3","key":"9183_CR57","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/hep.22073","volume":"47","author":"R Abdalian","year":"2008","unstructured":"Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 2008;47(3):949\u2013957","journal-title":"Hepatology"},{"issue":"2","key":"9183_CR58","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/hep.22380","volume":"48","author":"C O\u2019Brien","year":"2008","unstructured":"O\u2019Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008;48(2):550\u2013556","journal-title":"Hepatology"},{"issue":"3","key":"9183_CR59","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1089-3261(02)00023-5","volume":"6","author":"PT Donaldson","year":"2002","unstructured":"Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis 2002;6(3):707\u2013725","journal-title":"Clin Liver Dis"},{"issue":"4","key":"9183_CR60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cgh.2007.12.048","volume":"6","author":"AJ Czaja","year":"2008","unstructured":"Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008;6(4):379\u2013388","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"9183_CR61","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.510300611","volume":"30","author":"M Pando","year":"1999","unstructured":"Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999;30(6):1374\u20131380","journal-title":"Hepatology"},{"key":"9183_CR62","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.0105-2896.2006.00347.x","volume":"209","author":"G Anderson","year":"2006","unstructured":"Anderson G, Jenkinson WE, Jones T, Parnell SM, Kinsella FA, White AJ, et al. Establishment and functioning of intrathymic microenvironments. Immunol Rev 2006;209:10\u201327","journal-title":"Immunol Rev"},{"issue":"6","key":"9183_CR63","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.coi.2004.09.009","volume":"16","author":"MA Su","year":"2004","unstructured":"Su MA, Anderson MS. Aire: an update. Curr Opin Immunol 2004;16(6):746\u2013752","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"9183_CR64","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1172\/JCI34523","volume":"118","author":"MA Su","year":"2008","unstructured":"Su MA, Giang K, Zumer K, Jiang H, Oven I, Rinn JL, et al. Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in Aire. J Clin Invest 2008;118(5):1712\u20131726","journal-title":"J Clin Invest"},{"issue":"6","key":"9183_CR65","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jhep.2004.02.023","volume":"40","author":"I Djilali-Saiah","year":"2004","unstructured":"Djilali-Saiah I, Renous R, Caillat-Zucman S, Debray D, Alvarez F. Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients. J Hepatol 2004;40(6):904\u2013909","journal-title":"J Hepatol"},{"issue":"5","key":"9183_CR66","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1053\/jhep.2001.24031","volume":"33","author":"A Vogel","year":"2001","unstructured":"Vogel A, Liermann H, Harms A, Strassburg CP, Manns MP, Obermayer-Straub P. Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1. Hepatology 2001;33(5):1047\u20131052","journal-title":"Hepatology"},{"issue":"1","key":"9183_CR67","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1023\/A:1005670111068","volume":"46","author":"AJ Czaja","year":"2001","unstructured":"Czaja AJ, Santrach PJ, Breanndan MS. Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci 2001;46(1):140\u2013147","journal-title":"Dig Dis Sci"},{"issue":"3","key":"9183_CR68","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-2007-1007163","volume":"18","author":"G Mieli-Vergani","year":"1998","unstructured":"Mieli-Vergani G, Vergani D. Immunological liver diseases in children. Semin Liver Dis 1998;18(3):271\u2013279","journal-title":"Semin Liver Dis"},{"key":"9183_CR69","first-page":"A144","volume":"20","author":"AW Lohse","year":"1994","unstructured":"Lohse AW, Lohr H, Bilo K, Zumbuschenfelde KHM. Recognition and regulation of LKM-specific T-cell clones in LKM-positive autoimmune hepatitis. Hepatology 1994;20:A144.","journal-title":"Hepatology"},{"issue":"4","key":"9183_CR70","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1055\/s-2002-35705","volume":"22","author":"PT Donaldson","year":"2002","unstructured":"Donaldson PT. Genetics in autoimmune hepatitis. Semin Liver Dis 2002;22(4):353\u2013364","journal-title":"Semin Liver Dis"},{"issue":"5","key":"9183_CR71","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1568-9972(03)00017-X","volume":"2","author":"D Vergani","year":"2003","unstructured":"Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Autoimmun Rev 2003;2(5):241\u2013247","journal-title":"Autoimmun Rev"},{"issue":"2","key":"9183_CR72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1385\/CRIAI:18:2:127","volume":"18","author":"CP Strassburg","year":"2000","unstructured":"Strassburg CP, Obermayer-Straub P, Manns MP. Autoimmunity in liver diseases. Clin Rev Allergy Immunol 2000;18(2):127\u2013139","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"9183_CR73","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMra050408","volume":"354","author":"EL Krawitt","year":"2006","unstructured":"Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354(1):54\u201366","journal-title":"N Engl J Med"},{"issue":"6","key":"9183_CR74","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1084\/jem.20071859","volume":"205","author":"M Holdener","year":"2008","unstructured":"Holdener M, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med 2008;205(6):1409\u20131422","journal-title":"J Exp Med"},{"key":"9183_CR75","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-065X.1999.tb01319.x","volume":"169","author":"MS Horwitz","year":"1999","unstructured":"Horwitz MS, Sarvetnick N. Viruses, host responses, and autoimmunity. Immunol Rev 1999;169:241\u2013253","journal-title":"Immunol Rev"},{"issue":"6","key":"9183_CR76","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/ni1467","volume":"8","author":"EV Costa-Rodriguez","year":"2007","unstructured":"Costa-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007;8(6):639\u2013646","journal-title":"Nat Immunol"},{"issue":"2","key":"9183_CR77","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","volume":"24","author":"M Veldhoen","year":"2006","unstructured":"Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24(2):179\u2013189","journal-title":"Immunity"},{"issue":"9","key":"9183_CR78","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ni1497","volume":"8","author":"NJ Wilson","year":"2007","unstructured":"Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007;8(9):950\u2013957","journal-title":"Nat Immunol"},{"issue":"9","key":"9183_CR79","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ni1496","volume":"8","author":"EV Costa-Rodriguez","year":"2007","unstructured":"Costa-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8(9):942\u2013949","journal-title":"Nat Immunol"},{"issue":"6","key":"9183_CR80","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1084\/jem.20071450","volume":"205","author":"F Gerosa","year":"2008","unstructured":"Gerosa F, Baldani-Guerra B, Lyakh LA, Batoni G, Esin S, Winkler-Pickett RT, et al. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med 2008;205(6):1447\u20131461","journal-title":"J Exp Med"},{"issue":"6","key":"9183_CR81","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","volume":"126","author":"II Ivanov","year":"2006","unstructured":"Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006;126(6):1121\u20131133","journal-title":"Cell"},{"issue":"1","key":"9183_CR82","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2007.11.016","volume":"28","author":"XO Yang","year":"2008","unstructured":"Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008;28(1):29\u201339","journal-title":"Immunity"},{"issue":"28","key":"9183_CR83","doi-asserted-by":"crossref","first-page":"9721","DOI":"10.1073\/pnas.0804231105","volume":"105","author":"A Kimura","year":"2008","unstructured":"Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 2008;105(28):9721\u20139726","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"9183_CR84","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1084\/jem.20081438","volume":"206","author":"M Veldhoen","year":"2009","unstructured":"Veldhoen M, Hirota K, Christensen J, O\u2019Garra A, Stockinger B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 2009;206(1):43\u201349","journal-title":"J Exp Med"},{"issue":"1","key":"9183_CR85","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1021\/tx7001965","volume":"21","author":"LP Nguyen","year":"2008","unstructured":"Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon receptor. Chem Res Toxicol 2008;21(1):102\u2013116","journal-title":"Chem Res Toxicol"},{"issue":"2","key":"9183_CR86","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","volume":"201","author":"CL Langrish","year":"2005","unstructured":"Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201(2):233\u2013240","journal-title":"J Exp Med"},{"issue":"5804","key":"9183_CR87","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314(5804):1461\u20131463","journal-title":"Science"},{"issue":"9","key":"9183_CR88","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","volume":"103","author":"S Kotake","year":"1999","unstructured":"Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103(9):1345\u20131352","journal-title":"J Clin Invest"},{"issue":"5","key":"9183_CR89","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm0502-500","volume":"8","author":"C Lock","year":"2002","unstructured":"Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8(5):500\u2013558","journal-title":"Nat Med"},{"issue":"11","key":"9183_CR90","doi-asserted-by":"crossref","first-page":"7423","DOI":"10.4049\/jimmunol.180.11.7423","volume":"180","author":"J Pene","year":"2008","unstructured":"Pene J, Chevalier S, Preisser L, Venereau E, Guilleux MH, Ghannam S, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008;180(11):7423\u20137430","journal-title":"J Immunol"},{"issue":"2","key":"9183_CR91","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2249.2009.03947.x","volume":"157","author":"K Harada","year":"2009","unstructured":"Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol 2009;157(2):261\u2013270","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"9183_CR92","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0092-8674(00)80856-9","volume":"101","author":"S Sakaguchi","year":"2000","unstructured":"Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101(5):455\u2013458","journal-title":"Cell"},{"key":"9183_CR93","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","volume":"22","author":"S Sakaguchi","year":"2004","unstructured":"Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531\u2013562","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"9183_CR94","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ni1178","volume":"6","author":"S Sakaguchi","year":"2005","unstructured":"Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6(4):345\u2013352","journal-title":"Nat Immunol"},{"issue":"11","key":"9183_CR95","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1084\/jem.20050085","volume":"201","author":"CR Ruprecht","year":"2005","unstructured":"Ruprecht CR, Gattorno M, Ferlito F, Gregorio A, Martini A, Lanzavecchia A, et al. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med 2005;201(11):1793\u20131803","journal-title":"J Exp Med"},{"issue":"7","key":"9183_CR96","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1084\/jem.20060468","volume":"203","author":"N Seddiki","year":"2006","unstructured":"Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203(7):1693\u20131700","journal-title":"J Exp Med"},{"issue":"5609","key":"9183_CR97","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299(5609):1057\u20131061","journal-title":"Science"},{"issue":"8","key":"9183_CR98","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.4049\/jimmunol.161.8.3919","volume":"161","author":"G Boulougouris","year":"1998","unstructured":"Boulougouris G, McLeod JD, Patel YI, Ellwood CN, Walker LS, Sansom DM. Positive and negative regulation of human T cell activation mediated by the CTLA-4\/CD28 ligand CD80. J Immunol 1998;161(8):3919\u20133924","journal-title":"J Immunol"},{"issue":"1","key":"9183_CR99","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.510310110","volume":"31","author":"K Agarwal","year":"2000","unstructured":"Agarwal K, Czaja AJ, Jones DE, Donaldson PT. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology 2000;31(1):49\u201353","journal-title":"Hepatology"},{"issue":"2","key":"9183_CR100","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.21658","volume":"46","author":"MS Longhi","year":"2007","unstructured":"Longhi MS, Hussain MJ, Bogdanos DP, Quaglia A, Mieli-Vergani G, Ma Y, et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007;46(2):472\u2013484","journal-title":"Hepatology"},{"issue":"2","key":"9183_CR101","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/hep.22071","volume":"47","author":"MS Longhi","year":"2008","unstructured":"Longhi MS, Meda F, Wang P, Samyn M, Mieli-Vergani G, Vergani D, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008;47(2):581\u2013591","journal-title":"Hepatology"},{"issue":"7","key":"9183_CR102","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.4049\/jimmunol.176.7.4484","volume":"176","author":"MS Longhi","year":"2006","unstructured":"Longhi MS, Hussain MJ, Mitry RR, Arora SK, Mieli-Vergani G, Vergani D, et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006;176(7):4484\u20134491","journal-title":"J Immunol"},{"issue":"2","key":"9183_CR103","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1478-3231.2005.01211.x","volume":"26","author":"MJ Mayo","year":"2006","unstructured":"Mayo MJ, Mosby JM, Jeyarajah R, Combes B, Khilnani S, Al-halimi M, et al. The relationship between hepatic immunoglobulin production and CD154 expression in chronic liver diseases. Liver Int 2006;26(2):187\u2013196","journal-title":"Liver Int"},{"issue":"4","key":"9183_CR104","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0002-9440(10)62570-9","volume":"160","author":"AJ Grant","year":"2002","unstructured":"Grant AJ. Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease. Am J Pathol 2002;160(4):1445\u20131455","journal-title":"Am J Pathol"},{"issue":"7","key":"9183_CR105","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.autrev.2006.02.006","volume":"5","author":"Y Moritoki","year":"2006","unstructured":"Moritoki Y, Lian ZX, Ohsugi Y, Ueno Y, Gershwin ME. B cells and autoimmune liver diseases. Autoimmun Rev 2006;5(7):449\u2013457","journal-title":"Autoimmun Rev"},{"issue":"6","key":"9183_CR106","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1053\/jhep.2000.7878","volume":"31","author":"AJ Czaja","year":"2000","unstructured":"Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000;31(6):1231\u20131238","journal-title":"Hepatology"},{"issue":"2","key":"9183_CR107","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/hep.1840150208","volume":"15","author":"L Sanchez-Urdazpal","year":"1992","unstructured":"Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992;15(2):215\u2013221","journal-title":"Hepatology"},{"issue":"4","key":"9183_CR108","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1478-3231.2007.01444.x","volume":"27","author":"AJ Montano-Loza","year":"2007","unstructured":"Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007;27(4):507\u2013515","journal-title":"Liver Int"},{"issue":"2","key":"9183_CR109","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1034\/j.1600-0676.2003.00810.x","volume":"23","author":"AJ Czaja","year":"2003","unstructured":"Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003;23(2):116\u2013123","journal-title":"Liver Int"},{"key":"9183_CR110","first-page":"493","volume-title":"MacSween\u2019s Pathology of the Liver","author":"AJ Czaja","year":"2007","unstructured":"Czaja AJ, Carpenter HA. Autoimmune hepatitis. In Portmann BC, Ferrell LD, editors. MacSween\u2019s Pathology of the Liver. Edinburgh: Churchill Livingstone; 2007. 493\u2013517"},{"issue":"3","key":"9183_CR111","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0016-5085(83)90030-6","volume":"85","author":"AJ Czaja","year":"1983","unstructured":"Czaja AJ, Davis GL, Ludwig J, Baggenstoss AH, Taswell HF. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983;85(3):713\u2013717","journal-title":"Gastroenterology"},{"issue":"5","key":"9183_CR112","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s10620-006-9336-5","volume":"51","author":"AJ Czaja","year":"2006","unstructured":"Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006;51(5):968\u2013975","journal-title":"Dig Dis Sci"},{"issue":"3","key":"9183_CR113","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-0029-1233534","volume":"29","author":"CP Strassburg","year":"2009","unstructured":"Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin Liver Dis 2009;29(3):273\u2013285","journal-title":"Semin Liver Dis"},{"issue":"5","key":"9183_CR114","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1478-3231.2005.01122.x","volume":"25","author":"J Wiegand","year":"2005","unstructured":"Wiegand J, Schuler A, Kanzler S, Lohse A, Beuers U, Kreisel W, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005;25(5):927\u2013934","journal-title":"Liver Int"},{"issue":"6","key":"9183_CR115","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2036.1994.tb00334.x","volume":"8","author":"A Danielsson","year":"1994","unstructured":"Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994;8(6):585\u2013590","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"9183_CR116","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1053\/gast.2000.0010000001","volume":"119","author":"AJ Czaja","year":"2000","unstructured":"Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119(5):1312\u20131316","journal-title":"Gastroenterology"},{"issue":"9","key":"9183_CR117","first-page":"630","volume":"91","author":"BJ Rebollo","year":"1999","unstructured":"Rebollo BJ, Cifuentes MC, Pinar MA, Caunedo AA, Salas HE, Jimenez-Saenz M, et al. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis. Rev Esp Enferm Dig 1999;91(9):630\u2013638","journal-title":"Rev Esp Enferm Dig"},{"issue":"6","key":"9183_CR118","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0168-8278(05)80615-4","volume":"21","author":"KE Sherman","year":"1994","unstructured":"Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994;21(6):1040\u20131047","journal-title":"J Hepatol"},{"issue":"4","key":"9183_CR119","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/0016-5085(87)90454-9","volume":"93","author":"JS Hyams","year":"1987","unstructured":"Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987;93(4):890\u2013893","journal-title":"Gastroenterology"},{"issue":"5","key":"9183_CR120","first-page":"771","volume":"90","author":"DH van Thiel","year":"1995","unstructured":"van Thiel DH, Wright H, Carroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90(5):771\u2013776","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"9183_CR121","first-page":"571","volume":"35","author":"S Kanzler","year":"1997","unstructured":"Kanzler S, Gerken G, Dienes HP, Meyer zum Buschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis\u2014report of three cases. Z Gastroenterol 1997;35(7):571\u2013578","journal-title":"Z Gastroenterol"},{"issue":"1","key":"9183_CR122","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/gut.18.1.19","volume":"18","author":"RB Stern","year":"1977","unstructured":"Stern RB, Wilkinson SP, Howorth PJ, Williams R. Controlled trial of synthetic d-penicillamine and prednisone in maintenance therapy for active chronic hepatitis. Gut 1977;18(1):19\u201322","journal-title":"Gut"},{"issue":"5","key":"9183_CR123","first-page":"390","volume":"17","author":"RB Stern","year":"1976","unstructured":"Stern RB, Wilkinson SP, Williams R. Proceedings: controlled trial of d-penicillamine therapy in chronic active hepatitis. Gut 1976;17(5):390","journal-title":"Gut"},{"issue":"6","key":"9183_CR124","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0168-8278(98)80128-1","volume":"29","author":"KW Burak","year":"1998","unstructured":"Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998;29(6):990\u2013993","journal-title":"J Hepatol"},{"issue":"6","key":"9183_CR125","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/hep.510300603","volume":"30","author":"AJ Czaja","year":"1999","unstructured":"Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999;30(6):1381\u20131386","journal-title":"Hepatology"},{"issue":"5","key":"9183_CR126","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1155\/2004\/504591","volume":"18","author":"SM Devlin","year":"2004","unstructured":"Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004;18(5):321\u2013326","journal-title":"Can J Gastroenterol"},{"issue":"3","key":"9183_CR127","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0168-8278(00)80271-8","volume":"33","author":"PD Richardson","year":"2000","unstructured":"Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33(3):371\u2013375","journal-title":"J Hepatol"},{"issue":"1","key":"9183_CR128","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2009.02.024","volume":"51","author":"MM Aw","year":"2009","unstructured":"Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009;51(1):156\u2013160","journal-title":"J Hepatol"},{"issue":"12","key":"9183_CR129","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","volume":"103","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Oo YH, Schramm C, Denzer U, Buggisch P, Wiegard C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008;103(12):3063\u20133070","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"9183_CR130","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1478-3231.2006.01262.x","volume":"26","author":"ES Santos","year":"2006","unstructured":"Santos ES, Arosemena LR, Raez LE, O\u2019Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int 2006;26(5):625\u2013629","journal-title":"Liver Int"},{"issue":"10","key":"9183_CR131","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","volume":"101","author":"F Zaja","year":"2003","unstructured":"Zaja F, De VS, Mazzaro C, Sacco S, Damiani D, De MG, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101(10):3827\u20133834","journal-title":"Blood"},{"issue":"1","key":"9183_CR132","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/BOR.0b013e3282f1330c","volume":"20","author":"D Saadoun","year":"2008","unstructured":"Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008;20(1):23\u201328","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"9183_CR133","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1097\/01.tp.0000183749.79424.b4","volume":"80","author":"G Basse","year":"2005","unstructured":"Basse G, Ribes D, Kamar N, Mehrenberger M, Esposito L, Guitard J, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005;80(11):1560\u20131564","journal-title":"Transplantation"},{"issue":"7","key":"9183_CR134","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.transproceed.2006.06.131","volume":"38","author":"G Basse","year":"2006","unstructured":"Basse G, Ribes D, Kamar N, Mehrenberger M, Sallusto F, Esposito L, et al. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006;38(7):2308\u20132310","journal-title":"Transplant Proc"},{"issue":"4","key":"9183_CR135","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ajh.10043","volume":"68","author":"T Hamaki","year":"2001","unstructured":"Hamaki T, Kami M, Kusumi E, Ueyama J, Miyakoshi S, Morinaga S, et al. Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 2001;68(4):292\u2013294","journal-title":"Am J Hematol"},{"issue":"5","key":"9183_CR136","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1182\/blood-2003-05-1403","volume":"102","author":"TH Westhoff","year":"2003","unstructured":"Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102(5):1930","journal-title":"Blood"},{"issue":"11","key":"9183_CR137","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1038\/ajg.2009.433","volume":"104","author":"C Weiler-Normann","year":"2009","unstructured":"Weiler-Normann C, Wiegard C, Schramm C, Lohse AW. A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade. Am J Gastroenterol 2009;104(11):2877\u20132878","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"9183_CR138","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1136\/ard.2004.032821","volume":"64","author":"V Germano","year":"2005","unstructured":"Germano V, Picchianti DA, Baccano G, Natale E, Onetti MA, Priori R, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005;64(10):1519\u20131520","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"9183_CR139","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10067-005-0169-y","volume":"26","author":"GJ Tobon","year":"2007","unstructured":"Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol 2007;26(4):578\u2013581","journal-title":"Clin Rheumatol"},{"issue":"9","key":"9183_CR140","doi-asserted-by":"crossref","first-page":"524","DOI":"10.5694\/j.1326-5377.2007.tb01396.x","volume":"187","author":"G Ozorio","year":"2007","unstructured":"Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 2007;187(9):524\u2013526","journal-title":"Med J Aust"},{"issue":"3","key":"9183_CR141","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2230.2008.03088.x","volume":"34","author":"DA Fairhurst","year":"2009","unstructured":"Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriasis. Clin Exp Dermatol 2009;34(3):421\u2013422","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"9183_CR142","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/09546630310020470","volume":"14","author":"M Khanna","year":"2003","unstructured":"Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatol Treat 2003;14(4):229\u2013232","journal-title":"J Dermatol Treat"},{"issue":"12","key":"9183_CR143","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s10067-008-1000-3","volume":"27","author":"H Becker","year":"2008","unstructured":"Becker H, Willeke P, Domschke W, Gaubitz M. Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clin Rheumatol 2008;27(12):1597\u20131598","journal-title":"Clin Rheumatol"},{"issue":"5\u20136","key":"9183_CR144","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/09546630500424722","volume":"16","author":"G Goldenberg","year":"2005","unstructured":"Goldenberg G, Jorizzo JL. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatol Treat 2005;16(5\u20136):347\u2013349","journal-title":"J Dermatol Treat"},{"issue":"4","key":"9183_CR145","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/qjmed\/hcn006","volume":"101","author":"AW Morgan","year":"2008","unstructured":"Morgan AW, Hale G, Rebello PR, Richards SJ, Gooi HC, Waldmann H, et al. A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. QJM 2008;101(4):299\u2013306","journal-title":"QJM"},{"issue":"7","key":"9183_CR146","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/rheumatology\/kem072","volume":"46","author":"R Nixon","year":"2007","unstructured":"Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007;46(7):1140\u20131147","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"9183_CR147","doi-asserted-by":"crossref","first-page":"i21","DOI":"10.1136\/ard.59.suppl_1.i21","volume":"59","author":"N Nishimoto","year":"2000","unstructured":"Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000;59(Suppl 1):i21\u2013i27","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"9183_CR148","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jcp.55.2.81","volume":"55","author":"E Drewe","year":"2002","unstructured":"Drewe E, Powell RJ. Clinically useful monoclonal antibodies in treatment. J Clin Pathol 2002;55(2):81\u201385","journal-title":"J Clin Pathol"},{"issue":"Suppl 1","key":"9183_CR149","first-page":"S4","volume":"65","author":"JY Park","year":"2007","unstructured":"Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65(Suppl 1):S4\u2013S10","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"5","key":"9183_CR150","first-page":"758","volume":"25","author":"S Guignard","year":"2007","unstructured":"Guignard S, Dien G, Dougados M. Severe systemic inflammatory response syndrome in a patient with adult onset Still\u2019s disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol 2007;25(5):758\u2013759","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 1","key":"9183_CR151","doi-asserted-by":"crossref","first-page":"i81","DOI":"10.1136\/ard.59.suppl_1.i81","volume":"59","author":"WB van den Berg","year":"2000","unstructured":"van den Berg WB. Arguments for interleukin 1 as a target in chronic arthritis. Ann Rheum Dis 2000;59(Suppl 1):i81\u20134.","journal-title":"Ann Rheum Dis"},{"key":"9183_CR152","doi-asserted-by":"crossref","unstructured":"Genovese M, Van Den Bosch F, Roberson S, Bojin S, Biagini I, Ryan P, et al. LY2439821, a humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis. Arthritis Rheum (Epub 2010 Jan 21)","DOI":"10.1002\/art.27334"},{"key":"9183_CR153","unstructured":"Durez P, et al. AIN457, an anti-IL-17 antibody, shows good safety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind proof-of-concept trial. Ann Rheum Dis 2010;68(Suppl 3) (abstract LB.002)"},{"issue":"7","key":"9183_CR154","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/ni1083","volume":"5","author":"G Cinamon","year":"2004","unstructured":"Cinamon G, Matloubian M, Lesneski MJ, Xu Y, Low C, Lu T, et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol 2004;5(7):713\u2013720","journal-title":"Nat Immunol"},{"issue":"2 Suppl","key":"9183_CR155","doi-asserted-by":"crossref","first-page":"531S","DOI":"10.1016\/j.transproceed.2004.01.092","volume":"36","author":"BD Kahan","year":"2004","unstructured":"Kahan BD. FTY720: from bench to bedside. Transplant Proc 2004;36(2 Suppl):531S\u201343S","journal-title":"Transplant Proc"},{"key":"9183_CR156","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1034\/j.1600-065X.2003.00068.x","volume":"195","author":"H Rosen","year":"2003","unstructured":"Rosen H, Sanna G, Alfonso C. Egress: a receptor-regulated step in lymphocyte trafficking. Immunol Rev 2003;195:160\u2013177","journal-title":"Immunol Rev"},{"key":"9183_CR157","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1034\/j.1600-065X.2003.00075.x","volume":"195","author":"JG Cyster","year":"2003","unstructured":"Cyster JG. Lymphoid organ development and cell migration. Immunol Rev 2003;195:5\u201314","journal-title":"Immunol Rev"},{"issue":"10","key":"9183_CR158","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nri2400","volume":"8","author":"J Rivera","year":"2008","unstructured":"Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 2008;8(10):753\u2013763","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"9183_CR159","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMp068159","volume":"355","author":"S Massberg","year":"2006","unstructured":"Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate\u2014modifiers of lymphocyte migration. N Engl J Med 2006;355(11):1088\u20131091","journal-title":"N Engl J Med"},{"issue":"4","key":"9183_CR160","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/01.TP.0000151773.43266.17","volume":"79","author":"T Bohler","year":"2005","unstructured":"Bohler T, Budde K, Neumayer HH, Waiser J. Novel mediators of FTY720 in human lymphocytes. Transplantation 2005;79(4):492\u2013495","journal-title":"Transplantation"},{"issue":"1","key":"9183_CR161","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ni1534","volume":"9","author":"LG Ledgerwood","year":"2008","unstructured":"Ledgerwood LG, Lal G, Zhang N, Garin A, Esses SJ, Ginhoux F, et al. The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nat Immunol 2008;9(1):42\u201353","journal-title":"Nat Immunol"},{"issue":"1","key":"9183_CR162","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbrc.2006.04.067","volume":"345","author":"T Kaneko","year":"2006","unstructured":"Kaneko T, Murakami T, Kawana H, Takahashi M, Yasue T, Kobayashi E. Sphingosine-1-phosphate receptor agonists suppress concanavalin A-induced hepatic injury in mice. Biochem Biophys Res Commun 2006;345(1):85\u201392","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"9183_CR163","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1371\/journal.pbio.0060276","volume":"6","author":"KG Andersen","year":"2008","unstructured":"Andersen KG, Butcher T, Betz AG. Specific immunosuppression with inducible Foxp3-transduced polyclonal T cells. PLoS Biol 2008;6(11):e276","journal-title":"PLoS Biol"},{"issue":"2","key":"9183_CR164","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.clim.2008.12.008","volume":"131","author":"F Deknuydt","year":"2009","unstructured":"Deknuydt F, Bioley G, Valmori D, Ayyoub M. IL-1beta and IL-2 convert human Treg into T(H)17 cells. Clin Immunol 2009;131(2):298\u2013307","journal-title":"Clin Immunol"},{"issue":"12","key":"9183_CR165","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1073\/pnas.0900408106","volume":"106","author":"KS Voo","year":"2009","unstructured":"Voo KS, Wang YH, Santori FR, Boggiano C, Wang YH, Arima K, et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA 2009;106(12):4793\u20134798","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"9183_CR166","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2008-01-133967","volume":"112","author":"HJ Koenen","year":"2008","unstructured":"Koenen HJ, Smeets RL, Vink PM, van Rijseen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008;112(6):2340\u20132352","journal-title":"Blood"},{"issue":"3","key":"9183_CR167","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ni1317","volume":"7","author":"J Trowsdale","year":"2006","unstructured":"Trowsdale J, Betz AG. Mother\u2019s little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol 2006;7(3):241\u2013246","journal-title":"Nat Immunol"},{"issue":"2","key":"9183_CR168","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s00109-004-0608-2","volume":"83","author":"VR Aluvihare","year":"2005","unstructured":"Aluvihare VR, Kallikourdis M, Betz AG. Tolerance, suppression and the fetal allograft. J Mol Med 2005;83(2):88\u201396","journal-title":"J Mol Med"},{"issue":"4","key":"9183_CR169","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1478-3231.2005.01123.x","volume":"25","author":"YH Oo","year":"2005","unstructured":"Oo YH, Neuberger J. Use of mycophenolate in the treatment of autoimmune hepatitis. Liver Int 2005;25(4):687\u2013691","journal-title":"Liver Int"},{"issue":"2","key":"9183_CR170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.hepres.2006.06.007","volume":"36","author":"T Miyake","year":"2006","unstructured":"Miyake T, Miyaoka H, Abe M, Furukawa S, Shigematsu S, Furukawa E, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res 2006;36(2):139\u2013142","journal-title":"Hepatol Res"},{"issue":"3","key":"9183_CR171","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1055\/s-0029-1233531","volume":"29","author":"D Tripathi","year":"2009","unstructured":"Tripathi D, Neuberger J. Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease. Semin Liver Dis 2009;29(3):286\u2013296","journal-title":"Semin Liver Dis"},{"issue":"3","key":"9183_CR172","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1055\/s-0029-1233530","volume":"29","author":"AJ Czaja","year":"2009","unstructured":"Czaja AJ. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis 2009;29(3):315\u2013330","journal-title":"Semin Liver Dis"},{"issue":"2","key":"9183_CR173","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1432-2277.2008.00729.x","volume":"22","author":"TC Schreuder","year":"2009","unstructured":"Schreuder TC, Hubscher SG, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? Transpl Int 2009;22(2):144\u2013152","journal-title":"Transpl Int"},{"issue":"1","key":"9183_CR174","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1399-0012.2004.00117.x","volume":"18","author":"A Vogel","year":"2004","unstructured":"Vogel A, Heinrich E, Bahr MJ, Rifai K, Flemming P, Melter M, et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004;18(1):62\u201369","journal-title":"Clin Transplant"},{"issue":"Suppl 2","key":"9183_CR175","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1002\/lt.21916","volume":"15","author":"JC Duclos-Vallee","year":"2009","unstructured":"Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl 2009;15(Suppl 2):S25\u2013S34","journal-title":"Liver Transpl"},{"issue":"6","key":"9183_CR176","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/gut.52.6.893","volume":"52","author":"JC Duclos-Vallee","year":"2003","unstructured":"Duclos-Vallee JC, Sebagh M, Rifai K, Johanet C, Ballot E, Guettier C, et al. A 10\u00a0year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003;52(6):893\u2013897","journal-title":"Gut"},{"issue":"12","key":"9183_CR177","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/lt.20910","volume":"12","author":"M Gautam","year":"2006","unstructured":"Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12(12):1813\u20131824","journal-title":"Liver Transpl"},{"issue":"4","key":"9183_CR178","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1053\/jlts.2001.23085","volume":"7","author":"SG Hubscher","year":"2001","unstructured":"Hubscher SG. Recurrent autoimmune hepatitis after liver transplantation: diagnostic criteria, risk factors, and outcome. Liver Transpl 2001;7(4):285\u2013291","journal-title":"Liver Transpl"},{"issue":"4","key":"9183_CR179","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/jlts.2001.21449","volume":"7","author":"A Gonzalez-Koch","year":"2001","unstructured":"Gonzalez-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001;7(4):302\u2013310","journal-title":"Liver Transpl"},{"issue":"2","key":"9183_CR180","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/jhep.2002.31167","volume":"35","author":"M Salcedo","year":"2002","unstructured":"Salcedo M, Vaquero J, Banares R, Rodriguez-Mahou M, Alvarez E, Vicario JL, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002;35(2):349\u2013356","journal-title":"Hepatology"},{"issue":"9100","key":"9183_CR181","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0140-6736(97)06478-7","volume":"351","author":"N Kerkar","year":"1998","unstructured":"Kerkar N, Hadzic N, Davies ET, Portmann B, Donaldson PT, Rela M, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351(9100):409\u2013413","journal-title":"Lancet"},{"issue":"3","key":"9183_CR182","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.26756","volume":"34","author":"MA Heneghan","year":"2001","unstructured":"Heneghan MA, Portmann BC, Norris SM, Williams R, Muiesan P, Rela M, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001;34(3):464\u2013470","journal-title":"Hepatology"},{"issue":"1","key":"9183_CR183","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00007890-200201150-00015","volume":"73","author":"L D\u2019Antiga","year":"2002","unstructured":"D\u2019Antiga L, Dhawan A, Portmann B, Francavilla R, Rela M, Heaton N, et al. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. Transplantation 2002;73(1):80\u201384","journal-title":"Transplantation"},{"issue":"1","key":"9183_CR184","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.TP.0000132328.33460.43","volume":"78","author":"A Miyagawa-Hayashino","year":"2004","unstructured":"Miyagawa-Hayashino A, Haga H, Egawa H, Hayashino Y, Sakurai T, Minamiguchi S, et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 2004;78(1):128\u2013135","journal-title":"Transplantation"},{"issue":"1","key":"9183_CR185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jhep.2003.10.022","volume":"40","author":"G Mieli-Vergani","year":"2004","unstructured":"Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004;40(1):3\u20137","journal-title":"J Hepatol"},{"issue":"4","key":"9183_CR186","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1600-6143.2006.01717.x","volume":"7","author":"RS Venick","year":"2007","unstructured":"Venick RS, McDiarmid SV, Farmer DG, Gornbein J, Martin MG, Vargas JH, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transplant 2007;7(4):955\u2013963","journal-title":"Am J Transplant"},{"issue":"2","key":"9183_CR187","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MPG.0b013e31805ce219","volume":"45","author":"Y Avitzur","year":"2007","unstructured":"Avitzur Y, Ngan BY, Lao M, Fecteau A, Ng VL. Prospective evaluation of the prevalence and clinical significance of positive autoantibodies after pediatric liver transplantation. J Pediatr Gastroenterol Nutr 2007;45(2):222\u2013227","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"9183_CR188","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0168-8278(00)80175-0","volume":"33","author":"JC Duclos-Vallee","year":"2000","unstructured":"Duclos-Vallee JC, Johanet C, Bach JF, Yamamoto AM. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. J Hepatol 2000;33(1):163\u2013166","journal-title":"J Hepatol"},{"issue":"1","key":"9183_CR189","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0168-8278(99)80175-5","volume":"31","author":"AW Lohse","year":"1999","unstructured":"Lohse AW, Obermayer-Straub P, Gerken G, Brunner S, Altes U, Dienes HP, et al. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson\u2019s disease\u2014possible association with a steroid-resistant transplant rejection episode. J Hepatol 1999;31(1):149\u2013155","journal-title":"J Hepatol"},{"issue":"4","key":"9183_CR190","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/lt.20673","volume":"12","author":"S Riva","year":"2006","unstructured":"Riva S, Sonzogni A, Bravi M, Bertani A, Alessio MG, Candusso M, et al. Late graft dysfunction and autoantibodies after liver transplantation in children: preliminary results of an Italian experience. Liver Transpl 2006;12(4):573\u2013577","journal-title":"Liver Transpl"},{"issue":"6","key":"9183_CR191","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/lt.21447","volume":"14","author":"MI Fiel","year":"2008","unstructured":"Fiel MI, Agarwal K, Stanca C, Elhajj N, Kontorinis N, Thung SN, et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl 2008;14(6):861\u2013871","journal-title":"Liver Transpl"},{"issue":"3","key":"9183_CR192","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.tp.0000196716.07188.c4","volume":"81","author":"E Cholongitas","year":"2006","unstructured":"Cholongitas E, Samonakis D, Patch D, Senzolo M, Burroughs AK, Quaglia A, et al. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006;81(3):488\u2013490","journal-title":"Transplantation"},{"issue":"5","key":"9183_CR193","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/lt.20706","volume":"12","author":"N Kontorinis","year":"2006","unstructured":"Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006;12(5):827\u2013830","journal-title":"Liver Transpl"},{"issue":"2","key":"9183_CR194","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gut.2006.092064","volume":"56","author":"S Berardi","year":"2007","unstructured":"Berardi S, Lodato F, Gramenzi A, D\u2019Errico A, Lenzi M, Bontadini A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007;56(2):237\u2013242","journal-title":"Gut"},{"issue":"9","key":"9183_CR195","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/lt.20209","volume":"10","author":"I Aguilera","year":"2004","unstructured":"Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Transpl 2004;10(9):1166\u20131172","journal-title":"Liver Transpl"},{"issue":"9","key":"9183_CR196","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1016\/j.transproceed.2005.10.042","volume":"37","author":"I Aguilera","year":"2005","unstructured":"Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation. Transplant Proc 2005;37(9):3968\u20133969","journal-title":"Transplant Proc"},{"issue":"8","key":"9183_CR197","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/01.tp.0000259963.47350.da","volume":"83","author":"M Rodriguez-Mahou","year":"2007","unstructured":"Rodriguez-Mahou M, Salcedo M, Fernandez-Cruz E, Tiscar JL, Banares R, Clemente G, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with GSTT1 null genotype as prognostic marker: long-term follow-up after liver transplantation. Transplantation 2007;83(8):1126\u20131129","journal-title":"Transplantation"},{"issue":"5","key":"9183_CR198","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/lt.21721","volume":"15","author":"M Salcedo","year":"2009","unstructured":"Salcedo M, Rodriguez-Mahou M, Rodriguez-Sainz C, Rincon D, Alvarez E, Vicario JL, et al. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione-S-transferase T1 antibodies after liver transplantation. Liver Transpl 2009;15(5):530\u2013539","journal-title":"Liver Transpl"},{"issue":"3","key":"9183_CR199","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1399-0012.2007.00787.x","volume":"22","author":"K Yoshizawa","year":"2008","unstructured":"Yoshizawa K, Shirakawa H, Ichijo T, Umemura T, Tanaka E, Kiyosawa K, et al. De novo autoimmune hepatitis following living-donor liver transplantation for primary biliary cirrhosis. Clin Transplant 2008;22(3):385\u2013390","journal-title":"Clin Transplant"},{"key":"9183_CR200","unstructured":"Grammatikopoulos. AASLD; 2010 (abstract 706)"},{"issue":"3","key":"9183_CR201","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1399-0012.2007.00667.x","volume":"21","author":"A Richter","year":"2007","unstructured":"Richter A, Grabhorn E, Helmke K, Manns MP, Ganschow R, Burdelski M. Clinical relevance of autoantibodies after pediatric liver transplantation. Clin Transplant 2007;21(3):427\u2013432","journal-title":"Clin Transplant"},{"issue":"7","key":"9183_CR202","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/lt.21202","volume":"13","author":"OS Shaikh","year":"2007","unstructured":"Shaikh OS, Demetris AJ. Idiopathic posttransplantation hepatitis? Liver Transpl 2007;13(7):943\u2013946","journal-title":"Liver Transpl"},{"issue":"7","key":"9183_CR203","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/lt.21444","volume":"14","author":"D Herzog","year":"2008","unstructured":"Herzog D, Soglio DB, Fournet JC, Martin S, Marleau D, Alvarez F. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients. Liver Transpl 2008;14(7):946\u2013955","journal-title":"Liver Transpl"},{"issue":"5","key":"9183_CR204","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/hep.21152","volume":"43","author":"HM Evans","year":"2006","unstructured":"Evans HM. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006;43(5):1109\u20131117","journal-title":"Hepatology"},{"issue":"7","key":"9183_CR205","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/lt.21108","volume":"13","author":"WK Syn","year":"2007","unstructured":"Syn WK. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl 2007;13(7):984\u2013989","journal-title":"Liver Transpl"},{"issue":"Suppl 2","key":"9183_CR206","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1002\/lt.21902","volume":"15","author":"S Hubscher","year":"2009","unstructured":"Hubscher S. What does the long-term liver allograft look like for the pediatric recipient? Liver Transpl 2009;15(Suppl 2):S19\u2013S24","journal-title":"Liver Transpl"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-010-9183-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-010-9183-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-010-9183-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-010-9183-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T06:21:29Z","timestamp":1685600489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-010-9183-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,19]]},"references-count":206,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["9183"],"URL":"https:\/\/doi.org\/10.1007\/s12072-010-9183-5","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,19]]},"assertion":[{"value":"15 February 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}